Cellaïon is a biotechnology company based in Mont-St-Guibert, Belgium, that specializes in liver regenerative advanced therapy. Their flagship product, HepaStem®, is in advanced clinical development and targets severe liver diseases, particularly acute on chronic liver failure. Cellaïon recently announced an additional closing of 5.

5 million Euros financing, with Shinsei Capital Partners joining the syndicate of venture capital investors, along with existing investors Truffle Capital, Wallonie Entreprendre, and Newton Biocapital. This funding will support the ongoing phase 2b trial of HepaStem® in chronic liver disease patients with life-threatening acute liver failure. The investment from Shinsei Capital Partners signifies confidence in Cellaïon's capability to generate breakthroughs in regenerative liver medicine.

Cellaïon's goal is to expand its activities in Asia, Europe, and the US, where there is significant interest in the development of HepaStem®. They plan to obtain market approval for this first indication by the end of 2025, subject to positive clinical trial results and regulatory approval. HepaStem® offers hope for patients with acute hepatic failure, a condition that often leads to multi-system failure and has no current therapeutic alternative.

With its anti-inflammatory and regenerative signaling properties, HepaStem® aims to restore liver function and improve the survival rates of these patients. Cellaïon has developed a manufacturing method that allows for the easy administration of HepaStem® through intravenous infusion with excellent tolerance. The company has received support from various investors and holds a wide range of patents for its technology.

For more information, visit their website or contact Cellaïon directly